The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you could make more than that. To wit, the Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) ...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $1.97 per share. This compares to a loss of $0.06 per share a year ago. These ...

One of the prettiest stars in the winter evening sky has to be Rigel, the bright blue-white “foot” of the constellation Orion the Hunter. Actually, it is hard to say which is the prettiest star. After ...

Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical ...

As an analyst tracking small-cap biotech names, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has always been one of my favorites, thanks to the company’s evolution from a TAVALISSE-centric company to a ...

SOUTH SAN FRANCISCO, Calif., Sept. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Eli Lilly is paying Rigel Pharmaceuticals $125 million up front to grab a share in the development of drugs that would give the company a new way to address inflammation in multiple diseases. The ...